Compare Stocks: ATHE, ACB, PALI, and SIGA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACB Aurora Cannabis	$3.92 +0.5%	$3.68	$2.56 ▼ $6.66	$256.32M	0.63	730,456 shs	682,005 shs
ATHE Alterity Therapeutics	$3.45 -1.1%	$4.28	$2.66 ▼ $5.89	$62.54M	0.27	16,162 shs	47,167 shs
PALI Palisade Bio	$1.44 +0.7%	$1.92	$1.32 ▼ $2.86	$250.95M	1.61	3.94 million shs	1.99 million shs
SIGA Siga Technologies	$3.38 +0.9%	$3.15	$2.83 ▼ $9.17	$242.85M	1.04	629,765 shs	641,926 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACB Aurora Cannabis	+0.51%	-4.39%	-2.73%	+38.03%	-31.59%
ATHE Alterity Therapeutics	-1.15%	-5.99%	-23.67%	-35.63%	-12.66%
PALI Palisade Bio	+0.70%	-0.69%	-27.64%	-31.43%	+9.92%
SIGA Siga Technologies	+0.90%	-2.03%	+5.30%	-12.44%	-63.38%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACB Aurora Cannabis	$3.92 +0.5%	$3.68	$2.56 ▼ $6.66	$256.32M	0.63	730,456 shs	682,005 shs
ATHE Alterity Therapeutics	$3.45 -1.1%	$4.28	$2.66 ▼ $5.89	$62.54M	0.27	16,162 shs	47,167 shs
PALI Palisade Bio	$1.44 +0.7%	$1.92	$1.32 ▼ $2.86	$250.95M	1.61	3.94 million shs	1.99 million shs
SIGA Siga Technologies	$3.38 +0.9%	$3.15	$2.83 ▼ $9.17	$242.85M	1.04	629,765 shs	641,926 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACB Aurora Cannabis	+0.51%	-4.39%	-2.73%	+38.03%	-31.59%
ATHE Alterity Therapeutics	-1.15%	-5.99%	-23.67%	-35.63%	-12.66%
PALI Palisade Bio	+0.70%	-0.69%	-27.64%	-31.43%	+9.92%
SIGA Siga Technologies	+0.90%	-2.03%	+5.30%	-12.44%	-63.38%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACB Aurora Cannabis	2.50	Moderate Buy	N/A	N/A
ATHE Alterity Therapeutics	2.57	Moderate Buy	$10.00	189.86% Upside
PALI Palisade Bio	3.00	Buy	$9.83	582.87% Upside
SIGA Siga Technologies	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest ATHE, ACB, PALI, and SIGA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	PALI Palisade Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$7.00
9/16/2026	ACB Aurora Cannabis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/15/2026	ATHE Alterity Therapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
9/15/2026	ATHE Alterity Therapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
8/26/2026	ACB Aurora Cannabis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	ACB Aurora Cannabis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (E+)
8/11/2026	SIGA Siga Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/11/2026	ATHE Alterity Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$12.00
8/11/2026	ATHE Alterity Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$2.00
8/11/2026	ATHE Alterity Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
8/7/2026	ACB Aurora Cannabis	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACB Aurora Cannabis	$314.07M	0.82	$0.71 per share	5.56	$6.27 per share	0.63
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	$1.60 per share	N/A
PALI Palisade Bio	$500K	501.90	N/A	N/A	$0.87 per share	1.66
SIGA Siga Technologies	$53.66M	4.53	$0.34 per share	10.06	$2.78 per share	1.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACB Aurora Cannabis	-$88.13M	-$1.41	N/A	65.33	N/A	-32.26%	4.37%	3.45%	11/4/2026 (Estimated)
ATHE Alterity Therapeutics	-$15.88M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PALI Palisade Bio	-$16.78M	-$0.48	N/A	N/A	N/A	N/A	-33.47%	-31.79%	11/9/2026 (Estimated)
SIGA Siga Technologies	$23.28M	-$0.05	N/A	N/A	N/A	-5.19%	-1.55%	-1.32%	11/5/2026 (Estimated)

Latest ATHE, ACB, PALI, and SIGA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	PALI Palisade Bio	-$0.0522	-$0.05	+$0.0022	-$0.05	$0.50 million	$0.50 million
8/6/2026	Q2 2026	SIGA Siga Technologies	N/A	$0.17	N/A	$0.17	N/A	$41.00 million
8/5/2026	Q1 2027	ACB Aurora Cannabis	-$0.13	$0.04	+$0.17	-$0.05	$47.45 million	$47.62 million
7/30/2026	Q4 2026 TU	ATHE Alterity Therapeutics	N/A	-$0.28	N/A	-$0.28	N/A	$0.31 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACB Aurora Cannabis	N/A	N/A	N/A	N/A	N/A
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A
PALI Palisade Bio	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACB Aurora Cannabis	0.03	5.36	2.80
ATHE Alterity Therapeutics	N/A	14.52	14.52
PALI Palisade Bio	N/A	24.26	24.26
SIGA Siga Technologies	N/A	21.72	16.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACB Aurora Cannabis	47.63%
ATHE Alterity Therapeutics	2.14%
PALI Palisade Bio	11.79%
SIGA Siga Technologies	55.40%

Insider Ownership

Company	Insider Ownership
ACB Aurora Cannabis	0.01%
ATHE Alterity Therapeutics	38.80%
PALI Palisade Bio	0.07%
SIGA Siga Technologies	2.73%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACB Aurora Cannabis	1,028	65.72 million	65.72 million	Optionable
ATHE Alterity Therapeutics	11	18.13 million	11.09 million	Not Optionable
PALI Palisade Bio	14	174.27 million	174.15 million	Not Optionable
SIGA Siga Technologies	49	71.85 million	69.89 million	Optionable

ATHE, ACB, PALI, and SIGA Headlines

Recent News About These Companies

Siga Technologies Inc. $SIGA Shares Newly Purchased by Bank of America Corp DE

October 2 at 3:11 AM | marketbeat.com

SIGA Technologies stock holds value as small cap metrics guide investors

September 22, 2026 | ad-hoc-news.deA

SIGA Technologies stock gains on solid Q2 earnings and cash position

September 20, 2026 | ad-hoc-news.deA

NASDAQ Composite Index-Wert SIGA Technologies-Aktie: So viel hätten Anleger mit einem Investment in SIGA Technologies von vor einem Jahr verloren

September 8, 2026 | finanzen.netF

SIGA Tech (SIGA): Profits Drop 65%, But Cash and Special Payouts Remain

September 6, 2026 | insidermonkey.com

BlackRock Inc. Makes New $15.24 Million Investment in Siga Technologies Inc. $SIGA

September 4, 2026 | marketbeat.com

NASDAQ Composite Index-Wert SIGA Technologies-Aktie: So viel hätten Anleger mit einem Investment in SIGA Technologies von vor 10 Jahren verdient

August 31, 2026 | finanzen.netF

SIGA Technologies, Inc. (SIGA) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

SIGA Technologies 2026年第二季度每股收益$0.17，盘后股价小幅上涨

August 6, 2026 | cn.investing.com

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2026

August 6, 2026 | markets.businessinsider.com

SIGA to Host Business Update Call on August 6, 2026, Following Release of Second-Quarter 2026 Financial Results

July 30, 2026 | globenewswire.com

Siga Technologies: Q2 Earnings Due, New TPOXX Orders A Must

July 28, 2026 | seekingalpha.com

Is SIGA Technologies’ (SIGA) Index Shift and ESOP Shelf Registration Reframing Its Defensive Identity?

June 30, 2026 | finance.yahoo.com

Discovering SIGA Technologies And 2 Other Compelling Penny Stocks

May 22, 2026 | finance.yahoo.com

SIGA Technologies (SIGA) Is Down 9.9% After Q1 Revenue Miss And Sharper Net Loss - What's Changed

May 15, 2026 | finance.yahoo.com

Some Investors May Be Willing To Look Past SIGA Technologies' (NASDAQ:SIGA) Soft Earnings

May 14, 2026 | finance.yahoo.com

SIGA (SIGA) Q1 2026 Earnings Call Transcript

May 8, 2026 | fool.com

SIGA expects Q2 delivery of approximately $13M of oral TPOXX while targeting an FDA PEP submission in the next 12 months

May 8, 2026 | msn.com

SIGA Technologies, Inc. Q1 2026 Earnings Call Summary

May 8, 2026 | finance.yahoo.com

SIGA Technologies, Inc. (SIGA) Q1 2026 Earnings Call Transcript

May 8, 2026 | seekingalpha.com

SIGA Reports Financial Results for Three Months Ended March 31, 2026 and Provides Business Update

May 7, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ATHE, ACB, PALI, and SIGA Company Descriptions

Aurora Cannabis NASDAQ:ACB

$3.92 +0.02 (+0.51%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$3.90 -0.02 (-0.64%)

As of 10/2/2026 07:59 PM Eastern

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Alterity Therapeutics NASDAQ:ATHE

$3.45 -0.04 (-1.15%)

Closing price 10/2/2026 03:51 PM Eastern

Extended Trading

$3.33 -0.12 (-3.42%)

As of 10/2/2026 04:32 PM Eastern

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Palisade Bio NASDAQ:PALI

$1.44 +0.01 (+0.70%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.44 0.00 (0.00%)

As of 10/2/2026 07:30 PM Eastern

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

Siga Technologies NASDAQ:SIGA

$3.38 +0.03 (+0.90%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$3.42 +0.04 (+1.30%)

As of 10/2/2026 07:30 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATHE, ACB, PALI, and SIGA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATHE, ACB, PALI, and SIGA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATHE, ACB, PALI, and SIGA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ATHE, ACB, PALI, and SIGA Company Descriptions

Aurora Cannabis NASDAQ:ACB

Alterity Therapeutics NASDAQ:ATHE

Palisade Bio NASDAQ:PALI

Siga Technologies NASDAQ:SIGA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATHE, ACB, PALI, and SIGA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATHE, ACB, PALI, and SIGA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATHE, ACB, PALI, and SIGA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ATHE, ACB, PALI, and SIGA Company Descriptions

Aurora Cannabis NASDAQ:ACB

Alterity Therapeutics NASDAQ:ATHE

Palisade Bio NASDAQ:PALI

Siga Technologies NASDAQ:SIGA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools